Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT06821217
Recruiting Not applicable

The Effect of an App-based Intervention on Quality of Life in Patients With Endometriosis.

NCT06821217 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Not applicable
Started
2024-03-01
Last updated
2025-02-14

Condition(s) studied

EndometriosisPainQuality of LifeLife Style

Investigational drug(s) / intervention(s)

NALU Endo Flow App

NALU Endo Flow App: NALU Endo Flow App is a mobile application for women with endometriosis. The App provides educational information through videos, audios, and texts. Women learn about endometriosis in general with its symptoms, diagnosis, and therapy options such as lifestyle and mindset modification, endometriosis-specific diets, physical and mindfulness exercises. The App includes a diary to track the menstrual cycle and symptoms. Furthermore, access to a WhatsApp community of people with endometriosis is provided and a peer-group call is performed once monthly, as well as one additional monthly Q\&A (Question\&Answer) call moderated by certified health coaches.

Study summary

The goal of this clinical trial is to learn if an App-based intervention affects the quality of life in patients with suspected or confirmed endometriosis. The main questions it aims to answer are:

* Does the App-based intervention improve the quality of life?
* Does it lead to pain relief? Researchers will compare participants using the App to a control group to see if the App works to improve quality of life and endometriosis-related symptoms.

Participants will:

* Use an App-based intervention or be in the control group (no App-use) for 6 months
* Visit or have a telephone consultation after 3 and 6 months
* Complete a questionnaire to assess the quality of life at inclusion, after 1, 3 and 6 months

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Informed Consent as documented by signature * Age 18 or older * Premenopausal status (menopause is defined as amenorrhea lasting one year or longer) * Endometriosis, confirmed by surgery or clinically suspected * Possession of a smartphone Exclusion Criteria: * Planned endometriosis surgery or planned hormonal therapy in the study period * Surgery and/or new hormonal therapy in the last three months * Malignant diseases * Pregnancy * Breastfeeding * Active desire for pregnancy in the study period * Fertility treatment * Simultaneous participation in other intervention studies

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Gynecology and Obstetrics, Women's University Hospital, Inselspital Bern, University of Bern Bern Switzerland Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Switzerland

Clinical Outcomes After Acute Pulmonary Embolism Recruiting
PeRfusiOn Post tHrombEcTomy (PROPHET) Recruiting
Bern Human Organoid-Study to Study Host-microbe Interaction Recruiting
Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery Recruiting
Incidence of Slow Delta EEG Frequencies (0.1-1 Hz) Before Burst Suppression Starting soon

Other trials for the same condition

Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustments Starting soon
Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases Recruiting
Psychiatric Consultation-Liaison Intervention in Primary Care: A Pilot Study Recruiting
International CIPN Assessment and Validation Study Recruiting
Effect of Virtual Reality on Patient's Comfort During Cardiac Electronic Device Implantation. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06821217 on ClinicalTrials.gov ↗ ← All trials in Switzerland